Locations:
Search IconSearch

Tag: alzheimer’s disease (AD)

Brain gears concept
August 31, 2021/Geriatrics

Large NIA Award Accelerates Efforts of Cleveland Alzheimer’s Disease Research Center

$15.4M grant to fund work on atypical Alzheimer’s, Lewy body dementia and more

21-NEU-2210808_COVID-19-neurologic-manifestations_650x450

Study Suggests Mechanistic Overlap Between Alzheimer’s and COVID-19

Links are centered on neuroinflammation and microvascular injury, network medicine study finds

Patient on exercise bike
January 19, 2021/Geriatrics

CYCLE-AD Trial: High-Intensity Exercise to Stave Off Alzheimer’s Disease

New NIH-funded study tests home-based intervention in high-risk group

20-NEU-1971409_welcome-to-Nevada_650x450
September 18, 2020/Geriatrics

Getting Serious About Curbing Rural Disparities in Dementia Care and Research

NIA grant helps establish Nevada exploratory Alzheimer’s Disease Research Center

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

20-NEU-1929108_CQD_650x450_1206728074
August 13, 2020/Geriatrics

New Insights Into Inflammation-Related Pathways Predicting Cognitive Decline in Alzheimer’s

Longitudinal study implicates a specific pathway in mild cognitive impairment stage

20-NEU-1918414-alzheimer-brain-650×450

Studies of an Alpha-1 Adrenergic Agonist for Alzheimer’s Advance With New NIA Grant

$2 million will enable preclinical dose and efficacy testing of “compound 3”

Older woman close up

Newly Launched Alzheimer’s Center Is First in the Nation Focused Solely on Women

Mission centers on screening, prevention for at-risk women in their 30s to 60s

19-NEU-3860-alzheimer-brain-650×450
July 10, 2019/Geriatrics

Cleveland Alzheimer’s Disease Research Center to Be Created With $4.23 Million NIA Grant

Local population, deep expertise portend a center with high impact

18-NEU-Alzheimers-Brain-650×450

Funding Award Enables First Study to Examine Cognitive Effects of an Alpha-1 Agonist

Cleveland Clinic-developed “compound 3” begins testing in preclinical Alzheimer’s model

18-NEU-5506-Phase-3-Alzheimers-Trials-650×450
August 27, 2018/Geriatrics

Analysis of Alzheimer’s Drug Pipeline Reveals Slow Progress, a Few Bright Spots

Third annual report shows shift toward prevention studies, disease-modifying therapies

BackPage 3 of 4Next

Advertisement

Ad